Trade CRISPR Therapeutics AG - CRSP CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.13 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023401% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001179% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 0.1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 37.7 |
| Open | 37.19 |
| 1-Year Change | -35.59% |
| Day's Range | 37.19 - 37.99 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 17, 2025 | 37.71 | 0.51 | 1.37% | 37.20 | 38.04 | 36.95 |
| Apr 16, 2025 | 37.70 | -0.35 | -0.92% | 38.05 | 38.05 | 36.58 |
| Apr 15, 2025 | 38.87 | 0.50 | 1.30% | 38.37 | 39.75 | 38.37 |
| Apr 14, 2025 | 38.73 | -1.11 | -2.79% | 39.84 | 39.85 | 37.41 |
| Apr 11, 2025 | 39.19 | 4.88 | 14.22% | 34.31 | 39.19 | 34.31 |
| Apr 10, 2025 | 34.20 | 0.30 | 0.88% | 33.90 | 34.63 | 32.82 |
| Apr 9, 2025 | 34.72 | 4.57 | 15.16% | 30.15 | 34.95 | 30.15 |
| Apr 8, 2025 | 31.21 | -3.47 | -10.01% | 34.68 | 35.17 | 30.66 |
| Apr 7, 2025 | 32.33 | 1.77 | 5.79% | 30.56 | 33.75 | 29.95 |
| Apr 4, 2025 | 32.59 | 1.28 | 4.09% | 31.31 | 32.87 | 30.81 |
| Apr 3, 2025 | 32.60 | 0.57 | 1.78% | 32.03 | 33.59 | 32.03 |
| Apr 2, 2025 | 34.09 | 1.67 | 5.15% | 32.42 | 34.77 | 32.42 |
| Apr 1, 2025 | 32.97 | -0.81 | -2.40% | 33.78 | 34.83 | 32.95 |
| Mar 31, 2025 | 33.94 | -1.31 | -3.72% | 35.25 | 35.49 | 32.75 |
| Mar 28, 2025 | 36.93 | -0.84 | -2.22% | 37.77 | 38.09 | 36.85 |
| Mar 27, 2025 | 37.98 | -0.86 | -2.21% | 38.84 | 39.16 | 37.77 |
| Mar 26, 2025 | 39.12 | -1.38 | -3.41% | 40.50 | 40.78 | 39.00 |
| Mar 25, 2025 | 40.83 | -1.57 | -3.70% | 42.40 | 42.40 | 40.71 |
| Mar 24, 2025 | 42.54 | 0.79 | 1.89% | 41.75 | 42.65 | 41.75 |
| Mar 21, 2025 | 41.16 | 0.71 | 1.76% | 40.45 | 41.60 | 40.20 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
CRISPR Therapeutics AG Company profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious diseases. The company develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a revolutionary gene editing technology that allows for precise directed changes to genomic DNA. It has a portfolio of therapeutic programs in a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company''s lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient''s hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. The company is also developing CTX110, a donor-derived gene-edited allogeneic CAR-T therapy targeting cluster of differentiation 19 positive malignancies. In addition, it is developing allogeneic CAR-T programs comprising CTX120 targeting B-cell maturation antigen for the treatment of multiple myeloma; and CTX130 for the treatment of solid tumors and hematologic malignancies. Further, the company engages in developing regenerative medicine programs in diabetes; and in vivo and other genetic disease programs to treat glycogen storage disease Ia, duchenne muscular dystrophy, cystic fibrosis, and hurler syndrome. It partners with biopharma companies, academic centers, universities, and other organizations. The company has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to develop and commercialize products for the treatment of Duchenne M. CRISPR Therapeutics AG is headquartered in Zug, Switzerland.| Industry: | Biotechnology & Medical Research (NEC) |
Baarerstrasse 14
ZUG
ZUG 6300
CH
News
ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com